Ubamatamab clinical trials
Also written REGN4018.
How each study uses ubamatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ubamatamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Regeneron Pharmaceuticals (2) · M.D. Anderson Cancer Center (1) · ARCAGY/ GINECO GROUP (1)
Often tested with
Tested in the same studies.
Antineoplastic Agents (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ubamatamab.
- Jul 2027Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient MalignanciesPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses ubamatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Ubamatamab
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Regeneron PharmaceuticalsNCT07154290Written as Ubamatamab
- Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian CancerNot yet recruitingPhase 1/2ARCAGY/ GINECO GROUPNCT07637851Written as Ubamatamab
- Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient MalignanciesActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06444880Written as Ubamatamab
Given beside what is tested · 2 — ubamatamab is usual care or a partner of the new treatment
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03564340Written as Ubamatamab
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingPhase 1/2Regeneron PharmaceuticalsNCT04590326Written as Ubamatamab
Codes
What other systems call ubamatamab · ClinicalTrials.gg INT015242
- UNII (FDA) 6BUL1G4D60UBAMATAMABOne source FDA
- NCI Thesaurus C153129UbamatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6BUL1G4D60 | UBAMATAMAB | One source FDA |
| NCI Thesaurus | C153129 | Ubamatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.